Dominick J Angiolillo

Dominick J Angiolillo, MD, PhD, FACC

Chief, Division Of Cardiology; Medical Director, UF Health Cardiovascular Center – Jacksonville; Medical Director, Cardiovascular Research Program; Program Director, Interventional Cardiology Fellowship

Department: Medicine – Jacksonville
Business Phone: (904) 244-2655

About Dominick J Angiolillo

Dominick Angiolillo, M.D., Ph.D., graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in medicine and cardiology. He then pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. In 2004, Dr. Angiolillo joined the University of Florida College of Medicine – Jacksonville, where he is a professor of medicine with tenure status, director of cardiovascular research and director of the interventional cardiology fellowship program. He is staff cardiologist and interventional cardiologist on the UF Health Jacksonville campus. Dr. Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology. Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies. He has received national and international academic recognitions for this work. Recognitions include the 2013 Outstanding Achievement Award from the European Society of Cardiology and, since 2014, Dr. Angiolillo has been in the top 1 percent of most-cited researchers worldwide, according to Clarivate Analytics. Dr. Angiolillo has been a key investigator in the clinical development of numerous novel antithrombotic agents. He works alongside drug-regulating agencies in the United States and Europe toward approval of these drugs and product labeling updates. His success in obtaining extramural funding has allowed the development of one of the most active clinical research centers in the U.S. as well as one of the leading centers for thrombosis research in the world.

Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine. Due to his major contributions in antithrombotic therapy in patients with cardiovascular disease manifestations, Dr. Angiolillo has been invited to deliver lectures worldwide. His international visibility has allowed him to develop a very active research training program, attracting physicians and scientists from across the globe. In addition, Dr. Angiolillo has been a clinical mentor for years to residents and fellows, resulting in several Exemplary Teacher Awards. His leadership role as an academic clinician and scientist allows to him to nurture and promote career growth of many young trainees in the United States and abroad.

Dr. Angiolillo is an active member of many cardiovascular societies in the U.S. and Europe. In addition, he serves on the editorial board of numerous cardiovascular journals, some of which he holds leadership roles. He is a scientific reviewer for many major journals and extramural funding agencies, including the National Institutes of Health and other federal funding agencies in several European countries.

Board Certifications

  • Cardiovascular Disease
    American Board of Internal Medicine
  • Interventional Cardiology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Medicine
Subspecialties
  • Cardiovascular Disease
  • Interventional Cardiology

Publications

2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
JACC. Cardiovascular interventions. 14(17):1870-1883 [DOI] 10.1016/j.jcin.2021.07.016. [PMID] 34503737.
2021
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials.
Minerva cardiology and angiology. 69(4):398-407 [DOI] 10.23736/S2724-5683.20.05353-0. [PMID] 33258563.
2021
Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials.
Current opinion in cardiology. 36(4):390-396 [DOI] 10.1097/HCO.0000000000000879. [PMID] 33973929.
2021
Antithrombotic Management of Elderly Patients With Coronary Artery Disease.
JACC. Cardiovascular interventions. 14(7):723-738 [DOI] 10.1016/j.jcin.2021.01.040. [PMID] 33826494.
2021
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(1):59-66 [DOI] 10.4244/EIJ-D-20-00885. [PMID] 32928716.
2021
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
JACC. Cardiovascular interventions. 14(15):1688-1703 [DOI] 10.1016/j.jcin.2021.06.020. [PMID] 34353601.
2021
Antithrombotic therapy in diabetes: which, when, and for how long?
European heart journal. 42(23):2235-2259 [DOI] 10.1093/eurheartj/ehab128. [PMID] 33764414.
2021
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease.
Circulation. 144(16):1323-1343 [DOI] 10.1161/CIRCULATIONAHA.121.054305. [PMID] 34662163.
2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.
Circulation. 143(6):583-596 [DOI] 10.1161/CIRCULATIONAHA.120.050438. [PMID] 33555916.
2021
Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence.
The American journal of cardiology. 144 Suppl 1:S15-S22 [DOI] 10.1016/j.amjcard.2020.12.022. [PMID] 33706985.
2021
Bleeding avoidance strategies in percutaneous coronary intervention.
Nature reviews. Cardiology. [DOI] 10.1038/s41569-021-00598-1. [PMID] 34426673.
2021
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Journal of the American College of Cardiology. 78(15):1550-1563 [DOI] 10.1016/j.jacc.2021.08.013. [PMID] 34620413.
2021
Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI.
International journal of cardiology. 328:40-45 [DOI] 10.1016/j.ijcard.2020.11.042. [PMID] 33242504.
2021
Canakinumab for secondary prevention of coronary artery disease.
Future cardiology. 17(3):427-442 [DOI] 10.2217/fca-2020-0211. [PMID] 33533289.
2021
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
Journal of the American Heart Association. 10(13) [DOI] 10.1161/JAHA.121.022125. [PMID] 34212768.
2021
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Cardiovascular drugs and therapy. [DOI] 10.1007/s10557-021-07187-x. [PMID] 33860901.
2021
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 98(6):1111-1119 [DOI] 10.1002/ccd.29314. [PMID] 33038061.
2021
Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.
Journal of the American Heart Association. 10(3) [DOI] 10.1161/JAHA.120.019650. [PMID] 33228447.
2021
Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(6):443-444 [DOI] 10.4244/EIJV17I6A79. [PMID] 34413007.
2021
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
American heart journal. 231:147-156 [DOI] 10.1016/j.ahj.2020.09.019. [PMID] 33031789.
2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Journal of the American College of Cardiology. 78(21):2060-2072 [DOI] 10.1016/j.jacc.2021.08.074. [PMID] 34794687.
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ open diabetes research & care. 9(1) [DOI] 10.1136/bmjdrc-2020-001939. [PMID] 33637605.
2021
Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvab043. [PMID] 34146091.
2021
Evidence and Recommendations for Uninterrupted Versus Interrupted Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 14(7):764-767 [DOI] 10.1016/j.jcin.2021.02.019. [PMID] 33826496.
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Expert review of clinical pharmacology. 14(8):963-978 [DOI] 10.1080/17512433.2021.1927709. [PMID] 33993817.
2021
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvab068. [PMID] 34459481.
2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Lancet (London, England). 397(10283):1470-1483 [DOI] 10.1016/S0140-6736(21)00533-X. [PMID] 33865495.
2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI.
JACC. Cardiovascular interventions. 14(13):1434-1446 [DOI] 10.1016/j.jcin.2021.04.043. [PMID] 34238553.
2021
Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvab042. [PMID] 34114623.
2021
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.
Journal of thrombosis and thrombolysis. 52(2):419-428 [DOI] 10.1007/s11239-020-02321-2. [PMID] 33709255.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics. 109(3):705-715 [DOI] 10.1002/cpt.2039. [PMID] 32897581.
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions. 14(21):2410-2412 [DOI] 10.1016/j.jcin.2021.07.051. [PMID] 34736741.
2021
Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus.
Frontiers in pharmacology. 12 [DOI] 10.3389/fphar.2021.695961. [PMID] 34239442.
2021
Letter by Angiolillo et al Regarding Article, “Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial”.
Circulation. 143(13):e795-e796 [DOI] 10.1161/CIRCULATIONAHA.120.050205. [PMID] 33779271.
2021
Methodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results.
The Annals of thoracic surgery. 111(2):690-699 [DOI] 10.1016/j.athoracsur.2020.04.107. [PMID] 32540434.
2021
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation.
Journal of thrombosis and thrombolysis. 51(3):625-632 [DOI] 10.1007/s11239-020-02214-4. [PMID] 32803738.
2021
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management.
Nature reviews. Cardiology. 18(1):37-57 [DOI] 10.1038/s41569-020-0410-z. [PMID] 32759962.
2021
Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?
European heart journal. 42(39):4037-4039 [DOI] 10.1093/eurheartj/ehab595. [PMID] 34430973.
2021
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvab062. [PMID] 34374741.
2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1332. [PMID] 34135011.
2021
Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
JACC. Cardiovascular interventions. 14(12):1323-1333 [DOI] 10.1016/j.jcin.2021.04.022. [PMID] 34167672.
2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Journal of the American Heart Association. 10(4) [DOI] 10.1161/JAHA.120.017008. [PMID] 33559485.
2021
Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial.
Revista espanola de cardiologia (English ed.). [DOI] 10.1016/j.rec.2021.08.003. [PMID] 34561195.
2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention.
International journal of cardiology. 337:1-8 [DOI] 10.1016/j.ijcard.2021.05.012. [PMID] 34000356.
2021
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvab070. [PMID] 34519777.
2021
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions.
Expert opinion on drug safety. 20(1):9-21 [DOI] 10.1080/14740338.2021.1850691. [PMID] 33180563.
2021
Septal perforating artery originating from the ramus intermedius artery.
Coronary artery disease. [DOI] 10.1097/MCA.0000000000001059. [PMID] 34086613.
2021
Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel.
World neurosurgery. 156:e374-e380 [DOI] 10.1016/j.wneu.2021.09.075. [PMID] 34563718.
2021
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
JAMA cardiology. 6(9):1032-1041 [DOI] 10.1001/jamacardio.2021.1720. [PMID] 33991416.
2021
Systematic Assessment of Online Health Information for Coronary Revascularization.
JAMA internal medicine. 181(7):1003-1006 [DOI] 10.1001/jamainternmed.2021.1051. [PMID] 33871563.
2021
Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention.
Expert review of cardiovascular therapy. 19(6):519-535 [DOI] 10.1080/14779072.2021.1920925. [PMID] 33881367.
2021
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.
Thrombosis and haemostasis. 121(4):422-432 [DOI] 10.1055/s-0040-1718729. [PMID] 33171520.
2021
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
European heart journal. [DOI] 10.1093/eurheartj/ehab702. [PMID] 34662382.
2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.
European heart journal. [DOI] 10.1093/eurheartj/ehab533. [PMID] 34423374.
2021
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.
JACC. Cardiovascular interventions. 14(4):444-456 [DOI] 10.1016/j.jcin.2020.11.046. [PMID] 33602441.
2021
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
JAMA cardiology. 6(10):1121-1129 [DOI] 10.1001/jamacardio.2021.2228. [PMID] 34190967.
2021
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
JACC. Cardiovascular interventions. 14(17):1857-1866 [DOI] 10.1016/j.jcin.2021.06.028. [PMID] 34446390.
2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.
Journal of thrombosis and thrombolysis. 51(3):741-747 [DOI] 10.1007/s11239-021-02386-7. [PMID] 33582955.
2020
Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial.
Annals of internal medicine. 173(6):436-444 [DOI] 10.7326/M20-1806. [PMID] 32687741.
2020
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Expert review of cardiovascular therapy. 18(8):449-464 [DOI] 10.1080/14779072.2020.1792293. [PMID] 32662726.
2020
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience.
TH open : companion journal to thrombosis and haemostasis. 4(4):e437-e445 [DOI] 10.1055/s-0040-1721504. [PMID] 33376943.
2020
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.
Circulation. 142(22):2172-2188 [DOI] 10.1161/CIRCULATIONAHA.120.045465. [PMID] 33253005.
2020
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation.
Journal of thrombosis and thrombolysis. 49(3):337-343 [DOI] 10.1007/s11239-020-02051-5. [PMID] 32080811.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science. 13(3):473-481 [DOI] 10.1111/cts.12729. [PMID] 31758664.
2020
Clopidogrel drug interactions: a review of the evidence and clinical implications.
Expert opinion on drug metabolism & toxicology. 16(11):1079-1096 [DOI] 10.1080/17425255.2020.1814254. [PMID] 32835535.
2020
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
American heart journal. 224:10-16 [DOI] 10.1016/j.ahj.2020.03.005. [PMID] 32272255.
2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics. 22(11) [DOI] 10.1038/s41436-020-0931-1. [PMID] 32747766.
2020
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
JACC. Cardiovascular interventions. 13(5):606-617 [DOI] 10.1016/j.jcin.2020.01.226. [PMID] 32139218.
2020
Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.
Trials. 21(1) [DOI] 10.1186/s13063-020-04859-1. [PMID] 33234137.
2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Thrombosis and haemostasis. 120(8):1147-1158 [DOI] 10.1055/s-0040-1713376. [PMID] 32594508.
2020
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.
Nature reviews. Cardiology. 17(4):242-257 [DOI] 10.1038/s41569-019-0314-y. [PMID] 31953535.
2020
Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go?
JACC. Cardiovascular interventions. 13(19):2263-2265 [DOI] 10.1016/j.jcin.2020.07.005. [PMID] 32950420.
2020
Editorial commentary: Evolving paradigms in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine. 30(4):203-204 [DOI] 10.1016/j.tcm.2019.06.004. [PMID] 31230913.
2020
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
Circulation. 142(24):2316-2328 [DOI] 10.1161/CIRCULATIONAHA.120.051532. [PMID] 33315489.
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis. 120(1):83-93 [DOI] 10.1055/s-0039-1695772. [PMID] 31470444.
2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics. 22(11):1898-1902 [DOI] 10.1038/s41436-020-0894-2. [PMID] 32678355.
2020
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
American heart journal. 228:1-7 [DOI] 10.1016/j.ahj.2020.07.005. [PMID] 32739652.
2020
Fractional Flow Reserve-Based Coronary Artery Bypass Surgery: Current Evidence and Future Directions.
JACC. Cardiovascular interventions. 13(9):1086-1096 [DOI] 10.1016/j.jcin.2019.12.017. [PMID] 32222443.
2020
Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvaa095. [PMID] 32730628.
2020
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
Clinical research in cardiology : official journal of the German Cardiac Society. 109(7):930-943 [DOI] 10.1007/s00392-019-01586-9. [PMID] 31925529.
2020
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.
Journal of the American Heart Association. 9(24) [DOI] 10.1161/JAHA.120.018897. [PMID] 33289416.
2020
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
Circulation. 141(11):891-901 [DOI] 10.1161/CIRCULATIONAHA.119.041619. [PMID] 31992063.
2020
Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis.
JAMA internal medicine. 180(12):1638-1646 [DOI] 10.1001/jamainternmed.2020.4748. [PMID] 33044497.
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation. 142(15):1500-1502 [DOI] 10.1161/CIRCULATIONAHA.120.048770. [PMID] 33044856.
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association. 9(8) [DOI] 10.1161/JAHA.120.015865. [PMID] 32306797.
2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
European heart journal. 41(33):3132-3140 [DOI] 10.1093/eurheartj/ehz807. [PMID] 31994703.
2020
Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?
Thrombosis and haemostasis. 120(2):191-193 [DOI] 10.1055/s-0039-3400743. [PMID] 31899923.
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science. 5(5):419-428 [DOI] 10.1016/j.jacbts.2020.02.009. [PMID] 32478205.
2020
Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes.
Revista espanola de cardiologia (English ed.). 73(11):874-876 [DOI] 10.1016/j.rec.2020.05.003. [PMID] 32513627.
2020
Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent.
Journal of the American College of Cardiology. 76(10):1274-1275 [DOI] 10.1016/j.jacc.2020.07.018. [PMID] 32883424.
2020
Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Journal of the American Heart Association. 9(16) [DOI] 10.1161/JAHA.120.017212. [PMID] 32805186.
2020
Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development.
Expert opinion on investigational drugs. 29(6):537-546 [DOI] 10.1080/13543784.2020.1764533. [PMID] 32396484.
2020
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.
Journal of the American Heart Association. 9(7) [DOI] 10.1161/JAHA.119.014611. [PMID] 32223396.
2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
European heart journal. 41(37):3533-3545 [DOI] 10.1093/eurheartj/ehaa670. [PMID] 33085967.
2020
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
Cardiovascular diabetology. 19(1) [DOI] 10.1186/s12933-020-01153-x. [PMID] 33066794.
2020
Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.
Cardiovascular research. 116(7):e70-e72 [DOI] 10.1093/cvr/cvaa120. [PMID] 32406492.
2020
Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction: When the Choice Makes the Difference.
Circulation. 142(18):1709-1712 [DOI] 10.1161/CIRCULATIONAHA.120.050845. [PMID] 32867509.
2020
Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial.
Journal of the American College of Cardiology. 76(21):2569-2571 [DOI] 10.1016/j.jacc.2020.09.586. [PMID] 33213734.
2020
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
JACC. Cardiovascular interventions. 13(19):2238-2247 [DOI] 10.1016/j.jcin.2020.07.032. [PMID] 33032712.
2020
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Journal of the American College of Cardiology. 76(21):2436-2446 [DOI] 10.1016/j.jacc.2020.09.584. [PMID] 33213722.
2020
Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation. 142(24):2329-2337 [DOI] 10.1161/CIRCULATIONAHA.120.050244. [PMID] 33115278.
2020
Ticagrelor With or Without Aspirin After Complex PCI.
Journal of the American College of Cardiology. 75(19):2414-2424 [DOI] 10.1016/j.jacc.2020.03.011. [PMID] 32240761.
2020
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Journal of the American College of Cardiology. 75(6):578-586 [DOI] 10.1016/j.jacc.2019.11.056. [PMID] 32057371.
2020
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Journal of the American College of Cardiology. 75(19):2403-2413 [DOI] 10.1016/j.jacc.2020.03.008. [PMID] 32240760.
2020
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
Journal of the American College of Cardiology. 76(21):2450-2459 [DOI] 10.1016/j.jacc.2020.08.053. [PMID] 32882390.
2020
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel.
Journal of the American College of Cardiology. 76(12):1468-1483 [DOI] 10.1016/j.jacc.2020.06.085. [PMID] 32943165.
2020
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.
Journal of the American College of Cardiology. 75(21):2711-2722 [DOI] 10.1016/j.jacc.2020.03.070. [PMID] 32466887.
2020
When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y12 Inhibition Induced by Ticagrelor.
Journal of the American Heart Association. 9(24) [DOI] 10.1161/JAHA.120.019432. [PMID] 33302757.
2019
Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome.
Journal of the American College of Cardiology. 73(7):775-778 [DOI] 10.1016/j.jacc.2018.12.022. [PMID] 30784670.
2019
Aspirin for the primary prevention of cardiovascular disease: latest evidence.
Expert review of cardiovascular therapy. 17(9):633-643 [DOI] 10.1080/14779072.2019.1651199. [PMID] 31382819.
2019
Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression.
Thrombosis and haemostasis. 119(5):726-734 [DOI] 10.1055/s-0039-1678707. [PMID] 30759486.
2019
Atrial fibrillation, with ACS and PCI: walking a tightrope.
European heart journal. 40(19):1563-1566 [DOI] 10.1093/eurheartj/ehz192. [PMID] 30957836.
2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
JAMA cardiology. 4(11):1092-1101 [DOI] 10.1001/jamacardio.2019.3355. [PMID] 31557763.
2019
Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms.
Expert opinion on drug safety. 18(12):1171-1189 [DOI] 10.1080/14740338.2019.1680637. [PMID] 31623473.
2019
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.
Journal of thrombosis and thrombolysis. 48(1):1-10 [DOI] 10.1007/s11239-019-01860-7. [PMID] 31004312.
2019
De-escalation of oral P2Y12 inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 15(6):e486-e489 [DOI] 10.4244/EIJV15I6A89. [PMID] 31395576.
2019
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
Circulation. 140(3):240-261 [DOI] 10.1161/CIRCULATIONAHA.119.040167. [PMID] 31116032.
2019
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
European heart journal. 40(31):2632-2653 [DOI] 10.1093/eurheartj/ehz372. [PMID] 31116395.
2019
Dual antithrombotic therapy for atrial fibrillation and PCI.
Lancet (London, England). 394(10206):1300-1302 [DOI] 10.1016/S0140-6736(19)31954-3. [PMID] 31492502.
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions. 12(16):1538-1549 [DOI] 10.1016/j.jcin.2019.05.028. [PMID] 31377269.
2019
Emergency Consent: Patients’ and Surrogates’ Perspectives on Consent for Clinical Trials in Acute Stroke and Myocardial Infarction.
Journal of the American Heart Association. 8(2) [DOI] 10.1161/JAHA.118.010905. [PMID] 30663498.
2019
Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting.
Therapeutic advances in cardiovascular disease. 13 [DOI] 10.1177/1753944719891688. [PMID] 31814532.
2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.
Journal of the American Heart Association. 8(6) [DOI] 10.1161/JAHA.118.011139. [PMID] 30857464.
2019
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Therapeutic advances in cardiovascular disease. 13 [DOI] 10.1177/1753944719893274. [PMID] 31823688.
2019
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.
Journal of the American College of Cardiology. 74(1):83-99 [DOI] 10.1016/j.jacc.2019.05.016. [PMID] 31272556.
2019
Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation: The Certainty of Uncertainty.
JACC. Cardiovascular interventions. 12(16):1577-1579 [DOI] 10.1016/j.jcin.2019.04.014. [PMID] 31202953.
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science. 4(7):763-775 [DOI] 10.1016/j.jacbts.2019.07.011. [PMID] 31998847.
2019
Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies.
Interventional cardiology clinics. 8(4):321-340 [DOI] 10.1016/j.iccl.2019.05.001. [PMID] 31445718.
2019
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
British journal of clinical pharmacology. 85(2):413-421 [DOI] 10.1111/bcp.13812. [PMID] 30414387.
2019
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
Journal of thrombosis and thrombolysis. 48(4):554-562 [DOI] 10.1007/s11239-019-01933-7. [PMID] 31420787.
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation. 139(14):1661-1670 [DOI] 10.1161/CIRCULATIONAHA.118.038317. [PMID] 30630341.
2019
Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation: The Saga Continues.
Journal of the American College of Cardiology. 73(8):915-918 [DOI] 10.1016/j.jacc.2018.12.038. [PMID] 30819359.
2019
Reply: Platelet Function and Genetic Testing in Patients Receiving Oral Anticoagulation and Antiplatelet Treatment: An Area of Unmet Need.
JACC. Cardiovascular interventions. 12(18):1868-1869 [DOI] 10.1016/j.jcin.2019.07.040. [PMID] 31537291.
2019
Reply: Therapeutic Window of P2Y12 Inhibition: Should the Current Limits Be Modified?
JACC. Cardiovascular interventions. 12(23):2434-2435 [DOI] 10.1016/j.jcin.2019.10.015. [PMID] 31806222.
2019
Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.
Therapeutic advances in hematology. 10 [DOI] 10.1177/2040620719861475. [PMID] 31321012.
2019
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).
European heart journal. 40(25):2070-2085 [DOI] 10.1093/eurheartj/ehy377. [PMID] 29992264.
2019
Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes.
Journal of the American Heart Association. 8(13) [DOI] 10.1161/JAHA.119.013032. [PMID] 31242821.
2019
Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index.
Circulation. Cardiovascular quality and outcomes. 12(12) [DOI] 10.1161/CIRCOUTCOMES.119.006017. [PMID] 31822120.
2019
Tailoring Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: Navigating the Unknown.
JACC. Cardiovascular interventions. 12(1):33-37 [DOI] 10.1016/j.jcin.2018.10.047. [PMID] 30621975.
2019
Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Journal of the American Heart Association. 8(18) [DOI] 10.1161/JAHA.119.014000. [PMID] 31538837.
2019
The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy.
Thrombosis and haemostasis. 119(1):9-13 [DOI] 10.1055/s-0038-1676612. [PMID] 30597496.
2019
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
American heart journal. 208:81-90 [DOI] 10.1016/j.ahj.2018.11.008. [PMID] 30580130.
2019
Three-Dimensional Echocardiography for Transcatheter Aortic Valve Replacement Sizing: A Systematic Review and Meta-Analysis.
Journal of the American Heart Association. 8(19) [DOI] 10.1161/JAHA.119.013463. [PMID] 31549579.
2019
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
The New England journal of medicine. 381(16):1524-1534 [DOI] 10.1056/NEJMoa1908973. [PMID] 31475799.
2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
The New England journal of medicine. 381(21):2032-2042 [DOI] 10.1056/NEJMoa1908419. [PMID] 31556978.
2019
Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD.
JACC. Cardiovascular interventions. 12(16):1562-1565 [DOI] 10.1016/j.jcin.2019.06.032. [PMID] 31439337.
2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 12(16):1521-1537 [DOI] 10.1016/j.jcin.2019.03.034. [PMID] 31202949.
2018
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2.
JACC. Cardiovascular interventions. 11(5):417-434 [DOI] 10.1016/j.jcin.2017.10.051. [PMID] 29519377.
2018
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.
Journal of the American College of Cardiology. 72(23 Pt A):2915-2931 [DOI] 10.1016/j.jacc.2018.09.057. [PMID] 30522654.
2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
Circulation. 138(5):527-536 [DOI] 10.1161/CIRCULATIONAHA.118.034722. [PMID] 30571525.
2018
Aspirin for primary prevention of cardiovascular disease.
Lancet (London, England). 392(10152):988-990 [DOI] 10.1016/S0140-6736(18)31990-1. [PMID] 30158070.
2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Nature reviews. Cardiology. 15(8):480-496 [DOI] 10.1038/s41569-018-0049-1. [PMID] 29973709.
2018
Canakinumab for secondary prevention of atherosclerotic disease.
Expert opinion on biological therapy. 18(2):215-220 [DOI] 10.1080/14712598.2018.1420776. [PMID] 29265905.
2018
Cardiorenal Safety of OTC Analgesics.
Journal of cardiovascular pharmacology and therapeutics. 23(2):103-118 [DOI] 10.1177/1074248417751070. [PMID] 29421936.
2018
Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes.
Platelets. 29(3):309-311 [DOI] 10.1080/09537104.2017.1394452. [PMID] 29206072.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine. 16(1) [DOI] 10.1186/s12967-018-1469-8. [PMID] 29642909.
2018
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.
Expert opinion on investigational drugs. 27(12):997-1005 [DOI] 10.1080/13543784.2018.1543399. [PMID] 30376729.
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy. 8(5):594-609 [DOI] 10.21037/cdt.2018.05.09. [PMID] 30498684.
2018
Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography.
JACC. Cardiovascular interventions. 11(16):1601-1610 [DOI] 10.1016/j.jcin.2018.04.007. [PMID] 30139467.
2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.
Progress in cardiovascular diseases. 60(4-5):478-490 [DOI] 10.1016/j.pcad.2017.12.004. [PMID] 29291426.
2018
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease.
Expert opinion on drug safety. 17(10):1041-1052 [DOI] 10.1080/14740338.2018.1524869. [PMID] 30223690.
2018
High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome – Insight from the GEPRESS study.
International journal of cardiology. 259:20-25 [DOI] 10.1016/j.ijcard.2018.01.057. [PMID] 29579602.
2018
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity.
Thrombosis and haemostasis. 118(3):490-501 [DOI] 10.1055/s-0038-1629920. [PMID] 29448294.
2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation. Cardiovascular interventions. 11(4) [DOI] 10.1161/CIRCINTERVENTIONS.117.005635. [PMID] 29632238.
2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.
Blood advances. 2(6):715-730 [DOI] 10.1182/bloodadvances.2017013573. [PMID] 29588304.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics. 104(4):664-674 [DOI] 10.1002/cpt.1006. [PMID] 29280137.
2018
P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes.
Circulation. 138(15):1582-1596 [DOI] 10.1161/CIRCULATIONAHA.118.032078. [PMID] 30354508.
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation. 137(23):2450-2462 [DOI] 10.1161/CIRCULATIONAHA.118.033983. [PMID] 29526833.
2018
Pharmacogenomic Testing to Select Antiplatelet Therapy.
Journal of the American College of Cardiology. 71(17):1878-1881 [DOI] 10.1016/j.jacc.2018.03.021. [PMID] 29699613.
2018
Platelet Function or Genetic Testing for Guiding De-Escalation of Anti-Platelet Therapy: The Jury is Still Out.
Thrombosis and haemostasis. 118(9):1509-1511 [DOI] 10.1055/s-0038-1668546. [PMID] 30114718.
2018
Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.
Clinical cardiology. 41(8):1004-1008 [DOI] 10.1002/clc.22988. [PMID] 30033595.
2018
Response by Angiolillo et al to Letter Regarding Article, “International Expert Consensus Document on Switching Platelet P2Y12 Receptor Inhibiting Therapies”.
Circulation. 137(21):2310-2311 [DOI] 10.1161/CIRCULATIONAHA.118.033779. [PMID] 29784690.
2018
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Journal of cardiovascular pharmacology and therapeutics. 23(1):23-37 [DOI] 10.1177/1074248417708617. [PMID] 28565918.
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology. 11(2):151-164 [DOI] 10.1080/17512433.2017.1353909. [PMID] 28689434.
2018
Switching antiplatelet therapy in real-world clinical practice.
Cardiovascular revascularization medicine : including molecular interventions. 19(8):897-898 [DOI] 10.1016/j.carrev.2018.11.009. [PMID] 30551835.
2018
Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes.
Platelets. 29(5):528-530 [DOI] 10.1080/09537104.2018.1457782. [PMID] 29617211.
2018
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Expert review of hematology. 11(1):5-12 [DOI] 10.1080/17474086.2018.1400378. [PMID] 29091481.
2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.
Journal of the American College of Cardiology. 71(11):1243-1245 [DOI] 10.1016/j.jacc.2018.01.040. [PMID] 29544608.
2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
Journal of the American College of Cardiology. 71(5):489-496 [DOI] 10.1016/j.jacc.2017.11.050. [PMID] 29406853.
2018
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial.
American heart journal. 204:205-209 [DOI] 10.1016/j.ahj.2018.07.013. [PMID] 30149889.
2018
Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
Lancet (London, England). 392(10150):801-802 [DOI] 10.1016/S0140-6736(18)31921-4. [PMID] 30153987.
2017
Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention.
Interventional cardiology clinics. 6(1):xi-xii [DOI] 10.1016/j.iccl.2016.10.001. [PMID] 27886826.
2017
Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions.
JACC. Cardiovascular interventions. 10(5):425-437 [DOI] 10.1016/j.jcin.2016.12.279. [PMID] 28279311.
2017
Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 89(1):E13-E25 [DOI] 10.1002/ccd.26629. [PMID] 27404797.
2017
Antithrombotic therapy for acute coronary syndrome: Past, present and future.
Thrombosis and haemostasis. 117(7):1240-1248 [DOI] 10.1160/TH16-12-0963. [PMID] 28594051.
2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Nature reviews. Cardiology. 14(6):361-379 [DOI] 10.1038/nrcardio.2017.18. [PMID] 28230176.
2017
Antithrombotic Therapy for Prevention of Cerebral Thromboembolic Events After Transcatheter Aortic Valve Replacement: Evolving Paradigms and Ongoing Directions.
JACC. Cardiovascular interventions. 10(13):1366-1369 [DOI] 10.1016/j.jcin.2017.05.005. [PMID] 28527775.
2017
Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
Circulation. Cardiovascular interventions. 10(2) [DOI] 10.1161/CIRCINTERVENTIONS.116.004368. [PMID] 28193678.
2017
Clinical Pharmacology and Cardiovascular Safety of Naproxen.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 17(2):97-107 [DOI] 10.1007/s40256-016-0200-5. [PMID] 27826802.
2017
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
The American journal of cardiology. 119(8):1135-1140 [DOI] 10.1016/j.amjcard.2017.01.002. [PMID] 28202132.
2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thrombosis and haemostasis. 117(5):940-947 [DOI] 10.1160/TH16-09-0703. [PMID] 28300867.
2017
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 12(14):1681-1683 [DOI] 10.4244/EIJV12I14A276. [PMID] 28216470.
2017
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?
JACC. Cardiovascular interventions. 10(2):130-132 [DOI] 10.1016/j.jcin.2016.11.021. [PMID] 28104205.
2017
Dual antiplatelet therapy guided by platelet function testing.
Lancet (London, England). 390(10104):1718-1720 [DOI] 10.1016/S0140-6736(17)32279-1. [PMID] 28855079.
2017
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis. 44(3):355-361 [DOI] 10.1007/s11239-017-1541-x. [PMID] 28840456.
2017
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
Journal of the American College of Cardiology. 69(6):603-612 [DOI] 10.1016/j.jacc.2016.11.050. [PMID] 28089180.
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis. 117(1):201-203 [DOI] 10.1160/TH16-08-0594. [PMID] 27786340.
2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Journal of the American Heart Association. 6(4) [DOI] 10.1161/JAHA.117.005650. [PMID] 28356282.
2017
Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 89(2):190-198 [DOI] 10.1002/ccd.26428. [PMID] 26909669.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics. 18(5):421-426 [DOI] 10.2217/pgs-2017-0028. [PMID] 28346068.
2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Circulation. 136(20):1955-1975 [DOI] 10.1161/CIRCULATIONAHA.117.031164. [PMID] 29084738.
2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.
JACC. Cardiovascular interventions. 10(13):1374-1375 [DOI] 10.1016/j.jcin.2017.04.027. [PMID] 28683943.
2017
Oral trans-mucosal administration of ticagrelor: is this really the future?
Thrombosis and haemostasis. 117(5):826-828 [DOI] 10.1160/TH17-03-0177. [PMID] 28331923.
2017
Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear.
JACC. Cardiovascular interventions. 10(23):2464-2465 [DOI] 10.1016/j.jcin.2017.07.039. [PMID] 29153495.
2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis. 44(2):145-153 [DOI] 10.1007/s11239-017-1516-y. [PMID] 28608165.
2017
Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs?
Interventional cardiology clinics. 6(1):13-24 [DOI] 10.1016/j.iccl.2016.08.002. [PMID] 27886816.
2017
Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?
Journal of the American College of Cardiology. 69(23) [DOI] 10.1016/j.jacc.2017.03.599. [PMID] 28595709.
2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology. 69(2):250-251 [DOI] 10.1016/j.jacc.2016.09.982. [PMID] 28081837.
2017
Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 90(1):104-111 [DOI] 10.1002/ccd.26775. [PMID] 27566914.
2017
Switching P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics. 6(1):67-89 [DOI] 10.1016/j.iccl.2016.08.006. [PMID] 27886824.
2017
Tailoring duration of DAPT with risk scores.
Lancet (London, England). 389(10073):987-989 [DOI] 10.1016/S0140-6736(17)30591-3. [PMID] 28291000.
2017
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 17(2):109-121 [DOI] 10.1007/s40256-016-0202-3. [PMID] 27854064.
2017
The role of oral anticoagulant therapy in patients with acute coronary syndrome.
Therapeutic advances in hematology. 8(12):353-366 [DOI] 10.1177/2040620717733691. [PMID] 29204262.
2017
Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities: Don’t Throw Out the Baby With the Bath Water.
JACC. Cardiovascular interventions. 10(11):1086-1088 [DOI] 10.1016/j.jcin.2017.03.028. [PMID] 28527777.
2017
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery.
Journal of the American College of Cardiology. 69(14):1861-1870 [DOI] 10.1016/j.jacc.2017.02.012. [PMID] 28385315.
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal. 37(35):2722-30 [DOI] 10.1093/eurheartj/ehv744. [PMID] 26848148.
2016
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Expert opinion on drug safety. 15(2):275-85 [DOI] 10.1517/14740338.2016.1133585. [PMID] 26680584.
2016
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
Circulation journal : official journal of the Japanese Circulation Society. 80(4):791-801 [DOI] 10.1253/circj.CJ-16-0208. [PMID] 26984587.
2016
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease.
Nature reviews. Cardiology. 13(10):609-22 [DOI] 10.1038/nrcardio.2016.111. [PMID] 27489191.
2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.
Circulation. Cardiovascular interventions. 9(11) [PMID] 27803042.
View on: PubMed
2016
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
Circulation. 134(20):1579-1594 [PMID] 27729421.
View on: PubMed
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology. 67(17):1994-2004 [DOI] 10.1016/j.jacc.2016.02.045. [PMID] 27012781.
2016
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 9(3):228-230 [DOI] 10.1016/j.jcin.2015.11.022. [PMID] 26777325.
2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Thrombosis and haemostasis. 116(1):69-77 [DOI] 10.1160/TH15-12-0981. [PMID] 27009617.
2016
Dual antiplatelet therapy after coronary stenting.
Expert opinion on pharmacotherapy. 17(13):1775-87 [DOI] 10.1080/14656566.2016.1202924. [PMID] 27309035.
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis. 115(3):622-31 [DOI] 10.1160/TH15-06-0467. [PMID] 26633836.
2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Journal of the American College of Cardiology. 67(6):603-613 [DOI] 10.1016/j.jacc.2015.11.044. [PMID] 26868683.
2016
Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
European heart journal. Acute cardiovascular care. 5(5):475-86 [DOI] 10.1177/2048872615624849. [PMID] 26758542.
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis. 116(6):1060-1069 [PMID] 27488362.
View on: PubMed
2016
Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 16(6):391-397 [PMID] 27541144.
View on: PubMed
2016
Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty.
European heart journal. Acute cardiovascular care. 5(5):487-96 [DOI] 10.1177/2048872615594499. [PMID] 26163529.
2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
International journal of cardiology. 225:154-158 [DOI] 10.1016/j.ijcard.2016.09.125. [PMID] 27723533.
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation. 134(11):780-92 [DOI] 10.1161/CIRCULATIONAHA.116.023402. [PMID] 27559041.
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions. 9(11):1089-98 [DOI] 10.1016/j.jcin.2016.02.039. [PMID] 27013060.
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Journal of the American College of Cardiology. 67(10):1145-1154 [DOI] 10.1016/j.jacc.2015.12.062. [PMID] 26965534.
2016
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Journal of the American College of Cardiology. 67(23):2732-2740 [DOI] 10.1016/j.jacc.2016.03.529. [PMID] 27046160.
2016
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 12(3):312-8 [DOI] 10.4244/EIJV12I3A51. [PMID] 27320425.
2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Expert review of cardiovascular therapy. 14(7):811-20 [DOI] 10.1586/14779072.2016.1164035. [PMID] 26953527.
2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Heart (British Cardiac Society). 102(8):617-25 [DOI] 10.1136/heartjnl-2015-308963. [PMID] 26848185.
2016
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Nature reviews. Cardiology. 13(1):11-27 [DOI] 10.1038/nrcardio.2015.113. [PMID] 26283269.
2016
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
American heart journal. 182:125-134 [DOI] 10.1016/j.ahj.2016.09.006. [PMID] 27914492.
2016
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
Trends in cardiovascular medicine. 26(4):321-34 [DOI] 10.1016/j.tcm.2015.08.002. [PMID] 26391344.
2016
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.
Thrombosis and haemostasis. 115(4):844-55 [DOI] 10.1160/TH15-09-0742. [PMID] 26607655.
2015
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Giornale italiano di cardiologia (2006). 16(5):277-80 [DOI] 10.1714/1870.20424. [PMID] 25994462.
2015
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Journal of thrombosis and thrombolysis. 39(1):8-14 [DOI] 10.1007/s11239-014-1135-9. [PMID] 25305090.
2015
Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.
The American journal of cardiology. 115(5 Suppl):1A-2A [DOI] 10.1016/j.amjcard.2015.01.001. [PMID] 25728970.
2015
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
European heart journal. 36(27):1762-71 [DOI] 10.1093/eurheartj/ehv104. [PMID] 25896078.
2015
Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study.
Circulation. Cardiovascular interventions. 8(6) [DOI] 10.1161/CIRCINTERVENTIONS.114.001712. [PMID] 26025216.
2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
Journal of thrombosis and thrombolysis. 40(3):331-9 [DOI] 10.1007/s11239-015-1203-9. [PMID] 25761430.
2015
Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.
Circulation. Cardiovascular interventions. 8(6) [DOI] 10.1161/CIRCINTERVENTIONS.115.002760. [PMID] 26056251.
2015
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
European journal of pharmacology. 765:332-6 [DOI] 10.1016/j.ejphar.2015.08.059. [PMID] 26341013.
2015
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Thrombosis and haemostasis. 114(2):423-31 [DOI] 10.1160/TH14-12-1057. [PMID] 26017898.
2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Journal of thrombosis and thrombolysis. 40(3):317-22 [DOI] 10.1007/s11239-015-1233-3. [PMID] 26024789.
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions. 8(11):1457-1467 [DOI] 10.1016/j.jcin.2015.02.030. [PMID] 26404199.
2015
Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.
Journal of thrombosis and thrombolysis. 40(2):174-81 [DOI] 10.1007/s11239-015-1177-7. [PMID] 25633821.
2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Journal of the American Heart Association. 4(8) [DOI] 10.1161/JAHA.115.002171. [PMID] 26307570.
2015
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
European heart journal. 36(20):1252-63 [DOI] 10.1093/eurheartj/ehu523. [PMID] 25616646.
2015
Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI.
Thrombosis and haemostasis. 114(5):945-57 [DOI] 10.1160/TH15-03-0204. [PMID] 26202745.
2015
Novel antiplatelet agents in acute coronary syndrome.
Nature reviews. Cardiology. 12(1):30-47 [DOI] 10.1038/nrcardio.2014.156. [PMID] 25286881.
2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
Progress in cardiovascular diseases. 58(3):267-77 [DOI] 10.1016/j.pcad.2015.08.009. [PMID] 26277706.
2015
Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma.
Journal of thrombosis and thrombolysis. 39(2):203-8 [DOI] 10.1007/s11239-014-1132-z. [PMID] 25164314.
2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Thrombosis and haemostasis. 113(2):272-82 [DOI] 10.1160/TH14-05-0436. [PMID] 25274620.
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions. 8(8):1075-1083 [DOI] 10.1016/j.jcin.2015.02.022. [PMID] 26117466.
2015
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Cardiovascular revascularization medicine : including molecular interventions. 16(8):450-4 [DOI] 10.1016/j.carrev.2015.08.007. [PMID] 26440227.
2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Future cardiology. 11(5):547-64 [DOI] 10.2217/fca.15.50. [PMID] 26406386.
2015
Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.
Cardiovascular revascularization medicine : including molecular interventions. 16(5):266-71 [DOI] 10.1016/j.carrev.2015.05.011. [PMID] 26242981.
2015
Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
International journal of cardiology. 199:319-25 [DOI] 10.1016/j.ijcard.2015.07.064. [PMID] 26241637.
2015
Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines.
Circulation. Cardiovascular interventions. 8(3) [DOI] 10.1161/CIRCINTERVENTIONS.114.002301. [PMID] 25717045.
2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Journal of the American College of Cardiology. 65(16):1714-1715 [DOI] 10.1016/j.jacc.2014.12.069. [PMID] 25908082.
2015
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.
Journal of thrombosis and thrombolysis. 40(1):118-25 [DOI] 10.1007/s11239-014-1130-1. [PMID] 25129122.
2015
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Circulation. Cardiovascular interventions. 8(7) [DOI] 10.1161/CIRCINTERVENTIONS.114.002232. [PMID] 26152562.
2015
Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Circulation. 131(12):1047-53 [DOI] 10.1161/CIRCULATIONAHA.114.013774. [PMID] 25681464.
2014
Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing?
Journal of the American College of Cardiology. 64(9):872-4 [DOI] 10.1016/j.jacc.2014.06.1157. [PMID] 25169170.
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research. 7(1):53-63 [DOI] 10.1007/s12265-013-9535-3. [PMID] 24395495.
2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Journal of thrombosis and haemostasis : JTH. 12(4):560-3 [DOI] 10.1111/jth.12505. [PMID] 24428754.
2014
Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis. 37(3) [DOI] 10.1007/s11239-013-1003-z. [PMID] 24101257.
2014
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Journal of thrombosis and thrombolysis. 38(2):127-36 [DOI] 10.1007/s11239-013-0987-8. [PMID] 24043374.
2014
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Journal of cardiovascular translational research. 7(1):47-52 [DOI] 10.1007/s12265-013-9530-8. [PMID] 24357254.
2014
Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Journal of thrombosis and thrombolysis. 38(1):11-23 [DOI] 10.1007/s11239-013-1035-4. [PMID] 24368727.
2014
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
JACC. Cardiovascular interventions. 7(10):1117-27 [DOI] 10.1016/j.jcin.2014.04.020. [PMID] 25240538.
2014
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Journal of the American College of Cardiology. 63(7):619-629 [DOI] 10.1016/j.jacc.2013.10.022. [PMID] 24184169.
2014
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Journal of cardiovascular translational research. 7(1):39-46 [DOI] 10.1007/s12265-013-9533-5. [PMID] 24362676.
2014
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
Journal of the American College of Cardiology. 63(8):769-77 [DOI] 10.1016/j.jacc.2013.10.043. [PMID] 24239662.
2014
Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.
Journal of thrombosis and haemostasis : JTH. 12(2):126-37 [DOI] 10.1111/jth.12472. [PMID] 24298905.
2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Journal of the American College of Cardiology. 64(10):1005-14 [DOI] 10.1016/j.jacc.2014.06.1170. [PMID] 25190236.
2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Circulation. Cardiovascular interventions. 7(1):113-24 [DOI] 10.1161/CIRCINTERVENTIONS.113.001150. [PMID] 24550531.
2014
Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation.
JACC. Cardiovascular interventions. 7(7):810-6 [DOI] 10.1016/j.jcin.2013.11.026. [PMID] 24954573.
2014
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 10(1):38-46 [DOI] 10.4244/EIJV10I1A8. [PMID] 24832636.
2014
Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.
Current opinion in cardiology. 29(6):553-63 [DOI] 10.1097/HCO.0000000000000104. [PMID] 25144343.
2014
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
Journal of thrombosis and thrombolysis. 37(4):427-34 [DOI] 10.1007/s11239-013-0966-0. [PMID] 23852152.
2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
JACC. Cardiovascular interventions. 7(4):426-34 [DOI] 10.1016/j.jcin.2013.11.019. [PMID] 24630878.
2014
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis. 37(2):131-8 [DOI] 10.1007/s11239-013-0979-8. [PMID] 23943337.
2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Thrombosis and haemostasis. 111(2):258-65 [DOI] 10.1160/TH13-07-0529. [PMID] 24154863.
2014
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Journal of the American College of Cardiology. 63(15):1500-9 [DOI] 10.1016/j.jacc.2013.11.032. [PMID] 24333493.
2014
Platelet function testing in contemporary clinical and interventional practice.
Current treatment options in cardiovascular medicine. 16(5) [DOI] 10.1007/s11936-014-0300-y. [PMID] 24652579.
2014
Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis.
American heart journal. 168(4):530-6 [DOI] 10.1016/j.ahj.2014.06.026. [PMID] 25262263.
2014
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy–design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.
Journal of cardiovascular translational research. 7(1):91-100 [DOI] 10.1007/s12265-013-9527-3. [PMID] 24371012.
2014
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Thrombosis and haemostasis. 112(3):589-97 [DOI] 10.1160/TH13-10-0891. [PMID] 25008027.
2014
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Thrombosis research. 134(3):552-7 [DOI] 10.1016/j.thromres.2014.05.019. [PMID] 25022828.
2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Thrombosis and haemostasis. 112(2):311-22 [DOI] 10.1160/TH13-09-0747. [PMID] 24718367.
2014
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Vascular health and risk management. 10:177-88 [DOI] 10.2147/VHRM.S36045. [PMID] 24729713.
2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.
Journal of the American College of Cardiology. 64(4):361-8 [DOI] 10.1016/j.jacc.2014.03.051. [PMID] 25060370.
2013
‘Bridging Therapyandquot; With Low Molecular Weight Heparin in Patients With Coronary Stents Undergoing Surgery
. 34(1)
2013
Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 13(4):233-50 [DOI] 10.1007/s40256-013-0022-7. [PMID] 23613159.
2013
Antiplatelet therapy: new pharmacological agents and changing paradigms.
Journal of thrombosis and haemostasis : JTH. 11 Suppl 1:316-29 [DOI] 10.1111/jth.12219. [PMID] 23809135.
2013
Basics of Antithrombotic Therapy for Cardiovascular Disease: Pharmacologic Targets of Platelet Inhibitors and Anticoagulants.
Interventional cardiology clinics. 2(4):499-513 [DOI] 10.1016/j.iccl.2013.06.003. [PMID] 28582179.
2013
Cangrelor: a review on pharmacology and clinical trial development.
Expert review of cardiovascular therapy. 11(10):1279-91 [DOI] 10.1586/14779072.2013.837701. [PMID] 24138516.
2013
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
The Journal of pharmacology and experimental therapeutics. 344(3):665-72 [DOI] 10.1124/jpet.112.201640. [PMID] 23275066.
2013
Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
Thrombosis and haemostasis. 110(1):110-7 [DOI] 10.1160/TH13-01-0057. [PMID] 23615769.
2013
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
Journal of the American College of Cardiology. 62(24):2261-73 [DOI] 10.1016/j.jacc.2013.07.101. [PMID] 24076493.
2013
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Thrombosis and haemostasis. 109(2):347-55 [DOI] 10.1160/TH12-06-0378. [PMID] 23223867.
2013
Diabetes Mellitus, Cyp2C19 Genotype, and Pharmacodynamic Response To Clopidogrel Dosing: Insights From the Elevate-Timi 56 Trial
Circulation. 128(22, S)
2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
The New England journal of medicine. 368(14):1303-13 [DOI] 10.1056/NEJMoa1300815. [PMID] 23473369.
2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
Circulation. Cardiovascular interventions. 6(5):567-74 [DOI] 10.1161/CIRCINTERVENTIONS.112.000063. [PMID] 24065443.
2013
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.
Journal of thrombosis and thrombolysis. 35(2):155-64 [DOI] 10.1007/s11239-012-0846-z. [PMID] 23184484.
2013
Effects of Cangrelor in Prasugrel Treated Patients: a Pharmacodynamic in Vitro Investigation
Circulation. 128(22, S)
2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Thrombosis and haemostasis. 110(6):1223-31 [DOI] 10.1160/TH13-03-0263. [PMID] 24009042.
2013
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
JACC. Cardiovascular interventions. 6(2):169-79 [DOI] 10.1016/j.jcin.2012.09.013. [PMID] 23428009.
2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Thrombosis and haemostasis. 110(4):777-84 [DOI] 10.1160/TH13-05-0400. [PMID] 23884248.
2013
Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
JACC. Cardiovascular interventions. 6(2):182-4 [DOI] 10.1016/j.jcin.2012.10.007. [PMID] 23428011.
2013
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Journal of thrombosis and thrombolysis. 36(1):14-7 [DOI] 10.1007/s11239-012-0828-1. [PMID] 23143668.
2013
Impaired Responsiveness To Clopidogrel in Type 2 Diabetes: a Mechanistic Study
Circulation. 128(22, S)
2013
Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study (“Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo”).
Journal of thrombosis and thrombolysis. 35(2):165-74 [DOI] 10.1007/s11239-012-0834-3. [PMID] 23114538.
2013
Long-term outcomes of patients with acute coronary syndrome and nonobstructive coronary artery disease.
The American journal of cardiology. 112(2):150-5 [DOI] 10.1016/j.amjcard.2013.03.006. [PMID] 23602693.
2013
Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.
Circulation. 128(25):2785-98 [DOI] 10.1161/CIRCULATIONAHA.113.003675. [PMID] 24366588.
2013
Multi-Center Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity On Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
British Journal of Clinical Pharmacology. 75
2013
Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions: a Randomized Evaluation
Journal of the American College of Cardiology. 61
2013
Percutaneous coronary interventions in ST-segment-elevation myocardial infarction: shifting paradigms and future perspectives.
Circulation. Cardiovascular interventions. 6(6):593-5 [DOI] 10.1161/CIRCINTERVENTIONS.113.001060. [PMID] 24347653.
2013
Perioperative Management of Oral Antiplatelet Therapy in Patients With Coronary Stents Undergoing Surgery
. 34(1):880-881
2013
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 81(1):42-9 [DOI] 10.1002/ccd.24416. [PMID] 22431415.
2013
Pharmacodynamic Effects of Ev-077 in Patients With Diabetes Mellitus On Clopidogrel Monotherapy: Results of An in Vitro Pilot Investigation
Journal of the American College of Cardiology. 61
2013
Platelet function and genetic testing.
Journal of the American College of Cardiology. 62(17 Suppl):S21-31 [DOI] 10.1016/j.jacc.2013.08.704. [PMID] 24135660.
2013
Platelet function profiles in patients with diabetes mellitus.
Journal of cardiovascular translational research. 6(3):329-45 [DOI] 10.1007/s12265-013-9449-0. [PMID] 23404189.
2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Journal of the American College of Cardiology. 62(7):577-83 [DOI] 10.1016/j.jacc.2013.05.023. [PMID] 23747759.
2013
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Circulation. 127(6):673-80 [DOI] 10.1161/CIRCULATIONAHA.112.124248. [PMID] 23277305.
2013
Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome.
The American journal of cardiology. 111(3):439-44 [DOI] 10.1016/j.amjcard.2012.10.018. [PMID] 23168289.
2013
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
The heart surgery forum. 16(2):E60-9 [DOI] 10.1532/HSF98.20121103. [PMID] 23625478.
2013
Safety and Tolerability of Csl112 in Subjects With Stable Atherothrombotic Disease: Results From a Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study
Circulation. 128(22, S)
2013
Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 9(3):328-35 [DOI] 10.4244/EIJV9I3A54. [PMID] 23518240.
2013
Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice.
Journal of thrombosis and thrombolysis. 36(3):348-51 [DOI] 10.1007/s11239-012-0830-7. [PMID] 23143651.
2013
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 81(2):232-42 [DOI] 10.1002/ccd.24480. [PMID] 22581463.
2013
Switching from prasugrel to clopidogrel: navigating in unknown waters.
JACC. Cardiovascular interventions. 6(2):166-8 [DOI] 10.1016/j.jcin.2012.12.001. [PMID] 23428008.
2013
Targeting p-selectin during coronary interventions: the elusive link between inflammation and platelets to prevent myocardial damage.
Journal of the American College of Cardiology. 61(20):2056-9 [DOI] 10.1016/j.jacc.2013.03.004. [PMID] 23500231.
2013
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Journal of the American College of Cardiology. 62(6):505-12 [DOI] 10.1016/j.jacc.2013.03.037. [PMID] 23602770.
2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
Therapeutic advances in cardiovascular disease. 7(4):197-213 [DOI] 10.1177/1753944713487781. [PMID] 23818658.
2012
[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation].
Giornale italiano di cardiologia (2006). 13(7-8):528-51 [DOI] 10.1714/1114.12251. [PMID] 22781382.
2012
[The GRAVITAS study].
Giornale italiano di cardiologia (2006). 13(1):1-5 [DOI] 10.1714/1015.11050. [PMID] 22322466.
2012
A Comparison of 5 Mg Prasugrel With 75 Mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High On-Treatment Reactivity
Journal of the American College of Cardiology. 60
2012
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Journal of the American College of Cardiology. 59(24):2159-64 [DOI] 10.1016/j.jacc.2012.02.026. [PMID] 22520250.
2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Circulation. Cardiovascular interventions. 5(3):336-46 [DOI] 10.1161/CIRCINTERVENTIONS.111.964197. [PMID] 22647518.
2012
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Platelets. 23(7):537-51 [PMID] 22812566.
View on: PubMed
2012
Antithrombotic pharmacotherapy in the elderly: general issues and clinical conundrums.
Current treatment options in cardiovascular medicine. 14(1):57-68 [DOI] 10.1007/s11936-011-0153-6. [PMID] 22015931.
2012
Antithrombotic therapy in patients with chronic kidney disease.
Circulation. 125(21):2649-61 [DOI] 10.1161/CIRCULATIONAHA.111.084996. [PMID] 22644369.
2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Circulation. 125(8):978-86 [DOI] 10.1161/CIRCULATIONAHA.111.032912. [PMID] 22261200.
2012
Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program.
Journal of thrombosis and thrombolysis. 34(1):36-43 [DOI] 10.1007/s11239-012-0750-6. [PMID] 22653705.
2012
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Future cardiology. 8(4):503-11 [DOI] 10.2217/fca.12.35. [PMID] 22871190.
2012
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
JAMA. 307(3):265-74 [DOI] 10.1001/jama.2011.2002. [PMID] 22253393.
2012
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Current pharmaceutical design. 18(33):5273-93 [PMID] 22724415.
View on: PubMed
2012
Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
JACC. Cardiovascular interventions. 5(3):293-300 [DOI] 10.1016/j.jcin.2011.09.027. [PMID] 22440495.
2012
Clopidogrel Is Associated With Weaker Platelet Inhibition, Lower Active Metabolite Concentration and More Poor Responders in Higher Body Weight Patients Compared With Lower Body Weight Patients
. 33
2012
Effects of Pioglitazone On Platelet P2Y12 Mediated Signaling in Clopidogrel Treated Patients With Type 2 Diabetes Mellitus
Journal of the American College of Cardiology. 59
2012
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
Thrombosis and haemostasis. 108(5):930-6 [DOI] 10.1160/TH12-06-0397. [PMID] 22782352.
2012
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.
Circulation. 126(13):1645-62 [PMID] 23008471.
View on: PubMed
2012
High-Dose Atorvastatin Enhances Antiplatelet Effects of Double-Dose Clopidogrel
. 33
2012
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
Revista Espanola De Cardiologia. 65(1):105-106 [DOI] 10.1016/j.rec.2011.04.007.
2012
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Revista espanola de cardiologia (English ed.). 65(1):105-6 [DOI] 10.1016/j.recesp.2011.04.008. [PMID] 21783310.
2012
In Vitro Pharmacodynamic Effects of Ev-077, a New Inhibitor of Isoprostane and Prostanoid Cellular Activation
. 33
2012
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Journal of the American College of Cardiology. 59(22):1928-37 [DOI] 10.1016/j.jacc.2011.11.068. [PMID] 22624833.
2012
Long-Term Prognosis of Patients With Acute Coronary Syndrome and Non-Obstructive Coronary Artery Disease
. 33
2012
New directions in antiplatelet therapy.
Circulation. Cardiovascular interventions. 5(3):433-45 [DOI] 10.1161/CIRCINTERVENTIONS.111.966176. [PMID] 22715450.
2012
New Perspectives in Antiplatelet Therapy
. 19:406-427
2012
New perspectives in antiplatelet therapy.
Current medicinal chemistry. 19(3):406-27 [PMID] 22335515.
View on: PubMed
2012
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Journal of thrombosis and thrombolysis. 34(1):44-55 [DOI] 10.1007/s11239-012-0737-3. [PMID] 22569899.
2012
Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Journal of thrombosis and thrombolysis. 34(3):297-9 [PMID] 22923024.
View on: PubMed
2012
Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients On Maintenance Prasugrel Therapy Results of a Prospective Randomized Study
Journal of the American College of Cardiology. 59:1681-1687 [DOI] 10.1016/j.jacc.2011.12.039. [PMID] 22554598.
2012
Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study.
Journal of the American College of Cardiology. 59(19):1681-7 [DOI] 10.1016/j.jacc.2011.12.039. [PMID] 22554598.
2012
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Circulation. Cardiovascular interventions. 5(3):347-56 [DOI] 10.1161/CIRCINTERVENTIONS.111.965608. [PMID] 22619259.
2012
Pharmacokinetics and Pharmacodynamics of Prasugrel 5 Mg in Low Body Weight Patients and Prasugrel 10 Mg in Higher Body Weight Patients
. 33
2012
Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.
Journal of the American College of Cardiology. 59(10):891-900 [DOI] 10.1016/j.jacc.2011.09.075. [PMID] 22381424.
2012
Prasugrel
. 47:39-63
2012
Prasugrel 5Mg in the Very Elderly Is Non-Inferior To Prasugrel 10Mg in Non-Elderly Patients: the Generations Trial, a Pharmacodynamic (Pd) Study in Stable Cad Patients
. 33
2012
Prasugrel.
Advances in cardiology. 47:39-63 [DOI] 10.1159/000338044. [PMID] 22906902.
2012
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 80(3):395-405 [DOI] 10.1002/ccd.23337. [PMID] 22109961.
2012
Radial Access: Is There An Increased Risk of Operator Radiation Exposure During a Right Versus Left Radial Approach?
Journal of the American College of Cardiology. 60
2012
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Journal of the American College of Cardiology. 59(25):2338-43 [DOI] 10.1016/j.jacc.2012.02.042. [PMID] 22698488.
2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Journal of the American College of Cardiology. 60(20):2032-40 [DOI] 10.1016/j.jacc.2012.08.964. [PMID] 23083774.
2012
Response To Letter Regarding Article, “Antithrombotic Therapy in Patients With Chronic Kidney Disease”
Circulation. 126(21) [DOI] 10.1161/CIRCULATIONAHA.112.140582.
2012
Response To Letter Regarding Article, “Association of Proton Pump Inhibitor Use On Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From Plato”
Circulation. 126(11):E171-E172 [DOI] 10.1161/CIRCULATIONAHA.112.121665.
2012
Response To Letters Regarding Article, “Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: a Time-Dependent Analysis of the Gauging Responsiveness With a Verifynow P2Y12 Assay: Impact On Thrombosis and Safety (Gravitas) Trial”
Circulation. 125(14):E571-E572 [DOI] 10.1161/CIRCULATIONAHA.112.092239.
2012
Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
Journal of thrombosis and haemostasis : JTH. 10(10):2006-15 [DOI] 10.1111/j.1538-7836.2012.04869.x. [PMID] 22845871.
2012
Targeting platelet nitric oxide resistance with ramipril: unraveling mechanisms of atherothrombotic risk reduction with angiotensin-converting enzyme inhibitors.
Journal of the American College of Cardiology. 60(10):895-7 [DOI] 10.1016/j.jacc.2012.02.046. [PMID] 22682554.
2012
The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes From Aspirin To the Present Day
. 72:2087-2116
2012
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.
Drugs. 72(16):2087-116 [DOI] 10.2165/11640880-000000000-00000. [PMID] 23083110.
2012
The Influence of Body Weight On the Pharmacodynamic Response To Clopidogrel and Prasugrel: An Integrated Analysis of the Feather Study
. 33
2012
Transferring From Clopidogrel Loading Dose To Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High On-Treatment Platelet Reactivity Analysis of the Triplet Trial
Journal of the American College of Cardiology. 60
2011
[Antiplatelet and anticoagulant therapy in elderly patients].
Giornale italiano di cardiologia (2006). 12(3):186-97 [PMID] 21560475.
View on: PubMed
2011
[Assessment of dynamic coronary plaque changes and the clinical consequences in type-II diabetic patients: a serial intracoronary ultrasound study].
Revista espanola de cardiologia. 64(7):557-63 [DOI] 10.1016/j.recesp.2011.01.020. [PMID] 21641709.
2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
European heart journal. 32(7):838-46 [DOI] 10.1093/eurheartj/ehq494. [PMID] 21252171.
2011
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.
International journal of cardiology. 150(3):325-31 [DOI] 10.1016/j.ijcard.2010.08.035. [PMID] 20828843.
2011
Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
Future cardiology. 7(3):381-402 [DOI] 10.2217/fca.11.14. [PMID] 21627478.
2011
Antiplatelet therapy: thrombin receptor antagonists.
British journal of clinical pharmacology. 72(4):658-71 [DOI] 10.1111/j.1365-2125.2010.03884.x. [PMID] 21906120.
2011
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary.
Circulation. Cardiovascular interventions. 4(5):522-34 [DOI] 10.1161/CIRCINTERVENTIONS.111.965186. [PMID] 22010191.
2011
Applying platelet function testing in clinical practice: what are the unmet needs?
JAMA. 306(11):1260-1 [DOI] 10.1001/jama.2011.1349. [PMID] 21934063.
2011
Assessment of Dynamic Coronary Plaque Changes and the Clinical Consequences in Type-II Diabetic Patients: a Serial Intracoronary Ultrasound Study
Revista Espanola De Cardiologia. 64(7):557-563 [DOI] 10.1016/j.rec.2011.01.018.
2011
Can resistance to aspirin be reversed after an additional dose?
Journal of thrombosis and thrombolysis. 32(3):356-61 [DOI] 10.1007/s11239-011-0596-3. [PMID] 21614455.
2011
Clopidogrel-drug interactions.
Journal of the American College of Cardiology. 57(11):1251-63 [DOI] 10.1016/j.jacc.2010.11.024. [PMID] 21392639.
2011
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.
Thrombosis and haemostasis. 106(4):572-84 [DOI] 10.1160/TH11-04-0262. [PMID] 21785808.
2011
Current concepts on coronary revascularization in diabetic patients.
European heart journal. 32(22):2748-57 [DOI] 10.1093/eurheartj/ehr305. [PMID] 21893486.
2011
Diabetes and antiplatelet therapy in acute coronary syndrome.
Circulation. 123(7):798-813 [DOI] 10.1161/CIRCULATIONAHA.109.913376. [PMID] 21343595.
2011
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
Clinical pharmacology and therapeutics. 89(1):65-74 [DOI] 10.1038/clpt.2010.219. [PMID] 20844485.
2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
JAMA. 306(20):2221-8 [DOI] 10.1001/jama.2011.1703. [PMID] 22088980.
2011
Effects of Cangrelor On Platelet Function Profiles in Patients With Coronary Artery Disease: Results of An in Vitro Pharmacodynamic Investigation
Journal of the American College of Cardiology. 57
2011
Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study (“Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo”).
Heart (British Cardiac Society). 97(10):803-9 [DOI] 10.1136/hrt.2010.219949. [PMID] 21378389.
2011
Elevate-Timi 56: Escalating Clopidogrel By Involving a Genetic Strategy-Timi 56
Circulation. 124:2371-2372
2011
Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
Thrombosis and haemostasis. 105(4):730-2 [DOI] 10.1160/TH10-10-0652. [PMID] 21225097.
2011
Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease.
Thrombosis and haemostasis. 106(1):67-74 [DOI] 10.1160/TH10-12-0785. [PMID] 21655674.
2011
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Clinical therapeutics. 33(12):1883-93 [DOI] 10.1016/j.clinthera.2011.10.009. [PMID] 22078153.
2011
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Thrombosis and haemostasis. 106(2):253-62 [DOI] 10.1160/TH11-01-0041. [PMID] 21614414.
2011
Impact of Cangrelor On Multiple Platelet Signaling Pathways in Patients With Coronary Artery Disease
Journal of the American College of Cardiology. 57
2011
Impact of Concomitant and Staggered Pantoprazole Intake On Pharmacodynamic Effects Induced By Clopidogrel
Journal of the American College of Cardiology. 57
2011
Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study.
Journal of the American College of Cardiology. 58(13):1396-8 [DOI] 10.1016/j.jacc.2011.06.031. [PMID] 21920272.
View on: PubMed